The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
The Tumor Suppressor p53: From Structures to Drug Discovery
Open accessAbstract
Even 30 years after its discovery, the tumor suppressor protein p53 is still somewhat of an enigma. p53's intimate and multifaceted role in the cell cycle is mirrored in its equally complex structural biology that is being unraveled only slowly. Here, we discuss key structural aspects of p53 function and its inactivation by oncogenic mutations. Concerted action of folded and intrinsically disordered domains of the highly dynamic p53 protein provides binding promiscuity and specificity, allowing p53 to process a myriad of cellular signals to maintain the integrity of the human genome. Importantly, progress in elucidating the structural biology of p53 and its partner proteins has opened various avenues for structure-guided rescue of p53 function in tumors. These emerging anticancer strategies include targeting mutant-specific lesions on the surface of destabilized cancer mutants with small molecules and selective inhibition of p53's degradative pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p53 is a multi-domain transcription factor consisting of an N-terminal transactivation domain (NTAD), Pro-rich domain (PRD), DNA-binding domain (DBD), nuclear localization signal (NLS, residues 316-325), tetramerization domain (TET, residues 326-356), and C-terminal regulatory domain (CTD, residues 364-393)2 (Figure 1).”
From Mapping Interactions of the Intrinsically Disordered C-Terminal Regions of Tetrameric p53 by Segmental Isotope Labeling and NMR (2022) · cites this paper as [2]
In the citing paper
“It contains an N-terminal transactivation domain (TAD, residues 1–61), a proline-rich domain (PRD, residues 64–92), a DNA-binding domain (DBD, residues 96–292) linked to a tetramerization domain (TET, residues 324–356), and a C-terminal regulatory domain (CTD, residues 364–393)260,261 (Fig. 4b).”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [261]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820
CBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778
Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286
A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome
Wei, C.-L., Wu, Q., Vega, V. B., Chiu, K. P., Ng, P., Zhang, T., Shahab, A., Yong, H. C., Fu, Y., Weng, Z., et al. (2006) · Cell · doi:10.1016/j.cell.2005.10.043 · Cited by 1,141
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Function and structure of inherently disordered proteins
Dunker, A. K., Silman, I., Uversky, V. N., & Sussman, J. L. (2008) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2008.10.002 · Cited by 963
Oncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
Intrinsic Disorder in Transcription Factors
Liu, J., Perumal, N. B., Oldfield, C. J., Su, E. W., Uversky, V. N., & Dunker, A. K. (2006) · Biochemistry · doi:10.1021/bi0602718 · Cited by 792
Acetylation of the p53 DNA-binding domain regulates apoptosis induction.
Sykes, S. M., Mellert, H. S., Holbert, M. A., Li, K., Marmorstein, R., Lane, W. S., & McMahon, S. B. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.11.026 · Cited by 752
Analysis of Molecular Recognition Features (MoRFs)
Mohan, A., Oldfield, C. J., Radivojac, P., Vacic, V., Cortese, M. S., Dunker, A. K., & Uversky, V. N. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.07.087 · Cited by 751
Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors
Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 750
Stommel, J. M., Marchenko, N. D., Jimenez, G. S., Moll, U. M., Hope, T. J., & Wahl, G. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1660 · Cited by 738
A transcriptionally active DNA-binding site for human p53 protein complexes.
Funk, W. D., Pak, D. T., Karas, R. H., Wright, W. E., & Shay, J. W. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.6.2866 · Cited by 732
Tip60-Dependent Acetylation of p53 Modulates the Decision between Cell-Cycle Arrest and Apoptosis
Tang, Y., Luo, J., Zhang, W., & Gu, W. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.11.021 · Cited by 727
Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation
Leng, R. P., Lin, Y., Ma, W., Wu, H., Lemmers, B., Chung, S., Parant, J. M., Lozano, G., Hakem, R., & Benchimol, S. (2003) · Cell · doi:10.1016/s0092-8674(03)00193-4 · Cited by 722
The ubiquitin ligase COP1 is a critical negative regulator of p53
Dornan, D., Wertz, I., Shimizu, H., Arnott, D., Frantz, G. D., Dowd, P., O' Rourke, K., Koeppen, H., & Dixit, V. M. (2004) · Nature · doi:10.1038/nature02514 · Cited by 704
Ding, K., Lu, Y., Nikolovska-Coleska, Z., Wang, G., Qiu, S., Shangary, S., Gao, W., Qin, D., Stuckey, J., Krajewski, K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051122a · Cited by 702
Binding and modulation of p53 by p300/CBP coactivators
Lill, N. L., Grossman, S. R., Ginsberg, D., DeCaprio, J., & Livingston, D. M. (1997) · Nature · doi:10.1038/42981 · Cited by 693
Structural Biology of the Tumor Suppressor p53
Joerger, A. C., & Fersht, A. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.060806.091238 · Cited by 693
Self-citationThe genetics of the p53 pathway, apoptosis and cancer therapy
Vazquez, A., Bond, E. E., Levine, A. J., & Bond, G. L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2656 · Cited by 676
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660
Flexible nets: disorder and induced fit in the associations of p53 and 14-3-3 with their partners
Oldfield, C. J., Meng, J., Yang, J. Y., Yang, M. Q., Uversky, V. N., & Dunker, A. K. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-s1-s1 · Cited by 594
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Self-citationStructure of the p53 Tumor Suppressor Bound to the Ankyrin and SH3 Domains of 53BP2
Gorina, S., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.1001 · Cited by 571
Crystal Structure of the Tetramerization Domain of the p53 Tumor Suppressor at 1.7 Angstroms
Jeffrey, P. D., Gorina, S., & Pavletich, N. P. (1995) · Science · doi:10.1126/science.7878469 · Cited by 549
ARF-BP1/Mule Is a Critical Mediator of the ARF Tumor Suppressor
Chen, D., Kon, N., Li, M., Zhang, W., Qin, J., & Gu, W. (2005) · Cell · doi:10.1016/j.cell.2005.03.037 · Cited by 544
Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator
Lain, S., Hollick, J. J., Campbell, J., Staples, O. D., Higgins, M., Aoubala, M., McCarthy, A., Appleyard, V., Murray, K. E., Baker, L., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.03.004 · Cited by 522
DBC1 is a negative regulator of SIRT1
Kim, J.-E., Chen, J., & Lou, Z. (2008) · Nature · doi:10.1038/nature06500 · Cited by 505
On the shoulders of giants: p63, p73 and the rise of p53
Yang, A., Kaghad, M., Caput, D., & McKeon, F. (2002) · Trends in Genetics · doi:10.1016/s0168-9525(02)02595-7 · Cited by 486
Characterization of Molecular Recognition Features, MoRFs, and Their Binding Partners
Vacic, V., Oldfield, C. J., Mohan, A., Radivojac, P., Cortese, M. S., Uversky, V. N., & Dunker, A. K. (2007) · Journal of Proteome Research · doi:10.1021/pr0701411 · Cited by 483
Negative regulation of the deacetylase SIRT1 by DBC1
Zhao, W., Kruse, J.-P., Tang, Y., Jung, S. Y., Qin, J., & Gu, W. (2008) · Nature · doi:10.1038/nature06515 · Cited by 466
p53 Transcriptional Activation Mediated by Coactivators TAF II 40 and TAF II 60
Thut, C. J., Chen, J.-L., Klemm, R., & Tjian, R. (1995) · Science · doi:10.1126/science.7809597 · Cited by 439
Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain
Wells, M., Tidow, H., Rutherford, T. J., Markwick, P., Jensen, M. R., Mylonas, E., Svergun, D. I., Blackledge, M., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801353105 · Cited by 434
Self-citationStructure–function–rescue: the diverse nature of common p53 cancer mutants
Joerger, A. C., & Fersht, A. R. (2007) · Oncogene · doi:10.1038/sj.onc.1210291 · Cited by 434
Self-citationBullock, A. N., Henckel, J., & Fersht, A. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203434 · Cited by 434
Self-citationDiscovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells
Grasberger, B. L., Lu, T., Schubert, C., Parks, D. J., Carver, T. E., Koblish, H. K., Cummings, M. D., LaFrance, L. V., Milkiewicz, K. L., Calvo, R. R., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049137g · Cited by 432
Structural Basis of DNA Recognition by p53 Tetramers
Kitayner, M., Rozenberg, H., Kessler, N., Rabinovich, D., Shaulov, L., Haran, T. E., & Shakked, Z. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.05.015 · Cited by 408
Thermodynamic stability of wild-type and mutant p53 core domain
Bullock, A. N., Henckel, J., DeDecker, B. S., Johnson, C. M., Nikolova, P. V., Proctor, M. R., Lane, D. P., & Fersht, A. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14338 · Cited by 405
Self-citationStructural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX
Pazgier, M., Liu, M., Zou, G., Yuan, W., Li, C., Li, C., Li, J., Monbo, J., Zella, D., Tarasov, S. G., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900947106 · Cited by 391
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 387
Self-citationStructural basis for understanding oncogenic p53 mutations and designing rescue drugs
Joerger, A. C., Ang, H. C., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607286103 · Cited by 353
Self-citationKeeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4
Marine, J.-C., Francoz, S., Maetens, M., Wahl, G., Toledo, F., & Lozano, G. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401912 · Cited by 352
Molecular Mechanism of the Interaction between MDM2 and p53
Schon, O., Friedler, A., Bycroft, M., Freund, S. M. V., & Fersht, A. R. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00852-5 · Cited by 350
Self-citationLocal Structural Elements in the Mostly Unstructured Transcriptional Activation Domain of Human p53
Lee, H., Mok, K. H., Muhandiram, R., Park, K.-H., Suk, J.-E., Kim, D.-H., Chang, J., Sung, Y. C., Choi, K. Y., & Han, K.-H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003107200 · Cited by 329
Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells
Yang, Y., Ludwig, R. L., Jensen, J. P., Pierre, S. A., Medaglia, M. V., Davydov, I. V., Safiran, Y. J., Oberoi, P., Kenten, J. H., Phillips, A. C., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.029 · Cited by 322
Structural Mechanism of the Bromodomain of the Coactivator CBP in p53 Transcriptional Activation
Mujtaba, S., He, Y., Zeng, L., Yan, S., Plotnikova, O., Sachchidanand, Sanchez, R., Zeleznik-Le, N. J., Ronai, Z., & Zhou, M.-M. (2004) · Molecular Cell · doi:10.1016/s1097-2765(03)00528-8 · Cited by 319
Structure of the negative regulatory domain of p53 bound to S100B(betabeta).
Weber, D. J., Rust, R. R., & Baldisseri, D. M. (2000) · Nature Structural Biology · doi:10.1038/76797 · Cited by 314
A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer
DiGiammarino, E. L., Lee, A. S., Cadwell, C., Zhang, W., Bothner, B., Ribeiro, R. C., Zambetti, G., & Kriwacki, R. W. (2002) · Nature Structural Biology · doi:10.1038/nsb730 · Cited by 294
Sakaguchi, K., Saito, S., Higashimoto, Y., Roy, S., Anderson, C. W., & Appella, E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.13.9278 · Cited by 293
Trim24 targets endogenous p53 for degradation
Allton, K., Jain, A. K., Herz, H.-M., Tsai, W.-W., Jung, S. Y., Qin, J., Bergmann, A., Johnson, R. L., & Barton, M. C. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813177106 · Cited by 292
Linke, K., Mace, P. D., Smith, C. A., Vaux, D. L., Silke, J., & Day, C. L. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402309 · Cited by 288
Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A
Bochkareva, E., Kaustov, L., Ayed, A., Yi, G.-S., Lu, Y., Pineda-Lucena, A., Liao, J. C. C., Okorokov, A. L., Milner, J., Arrowsmith, C. H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504614102 · Cited by 275
p53 Contains Large Unstructured Regions in its Native State
Bell, S., Klein, C., Müller, L., Hansen, S., & Buchner, J. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00848-3 · Cited by 275
Friedler, A., Hansson, L. O., Veprintsev, D. B., Freund, S. M. V., Rippin, T. M., Nikolova, P. V., Proctor, M. R., Rüdiger, S., & Fersht, A. R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241629998 · Cited by 268
Self-citationSolution structure of the tetrameric minimum transforming domain of p53
Lee, W., Harvey, T. S., Yin, Y., Yau, P., Litchfield, D., & Arrowsmith, C. H. (1994) · Nature Structural & Molecular Biology · doi:10.1038/nsb1294-877 · Cited by 265
Cooperative Binding of Tetrameric p53 to DNA
Weinberg, R. L., Veprintsev, D. B., & Fersht, A. R. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.06.071 · Cited by 250
Self-citationSemirational design of active tumor suppressor p53 DNA binding domain with enhanced stability
Nikolova, P. V., Henckel, J., Lane, D. P., & Fersht, A. R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14675 · Cited by 240
Self-citationStructure of a Sir2 Enzyme Bound to an Acetylated p53 Peptide
Avalos, J. L., Celic, I., Muhammad, S., Cosgrove, M. S., Boeke, J. D., & Wolberger, C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00628-7 · Cited by 237
Crystal structure of the yeast MATα2/MCM1/DNA ternary complex
Tan, S., & Richmond, T. J. (1998) · Nature · doi:10.1038/35563 · Cited by 232
Marine, J.-C. W., Dyer, M. A., & Jochemsen, A. G. (2007) · Journal of Cell Science · doi:10.1242/jcs.03362 · Cited by 228
Refined solution structure of the oligomerization domain of the tumour suppressor p53
Clore, G. M., Ernst, J., Clubb, R., Omichinski, J. G., Kennedy, W. M. P., Sakaguchi, K., Appella, E., & Gronenborn, A. M. (1995) · Nature Structural & Molecular Biology · doi:10.1038/nsb0495-321 · Cited by 222
Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure
Joo, W. S., Jeffrey, P. D., Cantor, S. B., Finnin, M. S., Livingston, D. M., & Pavletich, N. P. (2002) · Genes & Development · doi:10.1101/gad.959202 · Cited by 220
Achatz, M. I. W., Olivier, M., Calvez, F. L., Martel-Planche, G., Lopes, A., Rossi, B. M., Ashton-Prolla, P., Giugliani, R., Palmero, E. I., Vargas, F. R., et al. (2007) · Cancer Letters · doi:10.1016/j.canlet.2005.12.039 · Cited by 217
Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2
Ferreon, J. C., Lee, C. W., Arai, M., Martinez-Yamout, M. A., Dyson, H. J., & Wright, P. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811023106 · Cited by 210
The rules of disorder or why disorder rules
Gsponer, J., & Madan Babu, M. (2009) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2009.03.001 · Cited by 199
Topors Functions as an E3 Ubiquitin Ligase with Specific E2 Enzymes and Ubiquitinates p53
Rajendra, R., Malegaonkar, D., Pungaliya, P., Marshall, H., Rasheed, Z., Brownell, J., Liu, L. F., Lutzker, S., Saleem, A., & Rubin, E. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c400300200 · Cited by 194
Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain
Popowicz, G., Czarna, A., & Holak, T. (2008) · Cell Cycle · doi:10.4161/cc.6365 · Cited by 194
Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53
Teufel, D. P., Freund, S. M., Bycroft, M., & Fersht, A. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702010104 · Cited by 192
Self-citationDi Lello, P., Jenkins, L. M. M., Jones, T. N., Nguyen, B. D., Hara, T., Yamaguchi, H., Dikeakos, J. D., Appella, E., Legault, P., & Omichinski, J. G. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.05.007 · Cited by 192
Mdmx as an essential regulator of p53 activity
Marine, J.-C., & Jochemsen, A. G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.151 · Cited by 188
Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor
Derbyshire, D. J. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf383 · Cited by 185
Structures of p53 Cancer Mutants and Mechanism of Rescue by Second-site Suppressor Mutations
Joerger, A. C., Ang, H. C., Veprintsev, D. B., Blair, C. M., & Fersht, A. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500179200 · Cited by 181
Self-citationSolution structure of p53 core domain: Structural basis for its instability
Cañadillas, J. M. P., Tidow, H., Freund, S. M. V., Rutherford, T. J., Ang, H. C., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510941103 · Cited by 174
Self-citationQuaternary structures of tumor suppressor p53 and a specific p53 DNA complex
Tidow, H., Melero, R., Mylonas, E., Freund, S. M. V., Grossmann, J. G., Carazo, J. M., Svergun, D. I., Valle, M., & Fersht, A. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705069104 · Cited by 170
Self-citationTargeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
Wade, M., & Wahl, G. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0423 · Cited by 170
Identification of a Novel p53 Functional Domain That Is Necessary for Mediating Apoptosis
Zhu, J., Zhou, W., Jiang, J., & Chen, X. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.21.13030 · Cited by 166
Koblish, H. K., Zhao, S., Franks, C. F., Donatelli, R. R., Tominovich, R. M., LaFrance, L. V., Leonard, K. A., Gushue, J. M., Parks, D. J., Calvo, R. R., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0199 · Cited by 165
Crystal Structure of a Superstable Mutant of Human p53 Core Domain
Joerger, A. C., Allen, M. D., & Fersht, A. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309732200 · Cited by 163
Self-citationSpecificity Determinants of Recruitment Peptides Bound to Phospho-CDK2/Cyclin A,
Lowe, E. D., Tews, I., Cheng, K. Y., Brown, N. R., Gul, S., Noble, M. E. M., Gamblin, S. J., & Johnson, L. N. (2002) · Biochemistry · doi:10.1021/bi0268910 · Cited by 162
Davison, T. S., Vagner, C., Kaghad, M., Ayed, A., Caput, D., & Arrowsmith, C. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.26.18709 · Cited by 160
Teufel, D. P., Bycroft, M., & Fersht, A. R. (2009) · Oncogene · doi:10.1038/onc.2009.71 · Cited by 159
Self-citationHow Many Mutant p53 Molecules Are Needed To Inactivate a Tetramer?
Chan, W. M., Siu, W. Y., Lau, A., & Poon, R. Y. C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3536-3551.2004 · Cited by 158
Gouas, D. A., Shi, H., & Hainaut, P. L. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.057 · Cited by 151
Mateu, M. G., & Fersht, A. R. (1998) · The EMBO Journal · doi:10.1093/emboj/17.10.2748 · Cited by 148
Self-citationBrachmann, R. K., Yu, K., Eby, Y., Pavletich, N. P., & Boeke, J. D. (1998) · The EMBO Journal · doi:10.1093/emboj/17.7.1847 · Cited by 142
Structural evolution of p53, p63, and p73: Implication for heterotetramer formation
Joerger, A. C., Rajagopalan, S., Natan, E., Veprintsev, D. B., Robinson, C. V., & Fersht, A. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905867106 · Cited by 142
Self-citationNicholls, C. D., McLure, K. G., Shields, M. A., & Lee, P. W. K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108815200 · Cited by 138
Ang, H. C., Joerger, A. C., Mayer, S., & Fersht, A. R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604209200 · Cited by 134
Self-citationStructural Basis for p300 Taz2-p53 TAD1 Binding and Modulation by Phosphorylation
Feng, H., Jenkins, L. M. M., Durell, S. R., Hayashi, R., Mazur, S. J., Cherry, S., Tropea, J. E., Miller, M., Wlodawer, A., Appella, E., et al. (2009) · Structure · doi:10.1016/j.str.2008.12.009 · Cited by 134
Kinetic Instability of p53 Core Domain Mutants
Friedler, A., Veprintsev, D. B., Hansson, L. O., & Fersht, A. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302458200 · Cited by 133
Self-citationLilyestrom, W., Klein, M. G., Zhang, R., Joachimiak, A., & Chen, X. S. (2006) · Genes & Development · doi:10.1101/gad.1456306 · Cited by 132
Increased apoptosis induction by 121F mutant p53
Saller, E., Tom, E., Brunori, M., Otter, M., Estreicher, A., Mack, D. H., & Iggo, R. D. (1999) · The EMBO Journal · doi:10.1093/emboj/18.16.4424 · Cited by 124
Molecular basis of Pirh2-mediated p53 ubiquitylation
Sheng, Y., Laister, R. C., Lemak, A. S., Wu, B., Tai, E., Duan, S., Lukin, J. A., Sunnerhagen, M., Srisailam, S., Karra, M., et al. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1521 · Cited by 123
Dearth, L. R., Qian, H., Wang, T., Baroni, T. E., Zeng, J., Chen, S. W., Yi, S. Y., & Brachmann, R. K. (2007) · Carcinogenesis · doi:10.1093/carcin/bgl132 · Cited by 120
Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide
Issaeva, N., Friedler, A., Bozko, P., Wiman, K. G., Fersht, A. R., & Selivanova, G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1835733100 · Cited by 118
Self-citationMapping the Interactions of the p53 Transactivation Domain with the KIX Domain of CBP
Lee, C. W., Arai, M., Martinez‐Yamout, M. A., Dyson, H. J., & Wright, P. E. (2009) · Biochemistry · doi:10.1021/bi802055v · Cited by 118
van Dieck, J., Fernández-Fernández, M. R., Veprintsev, D. B., & Fersht, A. R. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m901351200 · Cited by 118
Self-citationStructure of the p53 Core Domain Dimer Bound to DNA
Ho, W. C., Fitzgerald, M. X., & Marmorstein, R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603634200 · Cited by 118
Redefining the p53 response element
Wang, B., Xiao, Z., & Ren, E. C. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903284106 · Cited by 116
The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity
Okorokov, A. L., Sherman, M. B., Plisson, C., Grinkevich, V., Sigmundsson, K., Selivanova, G., Milner, J., & Orlova, E. V. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601382 · Cited by 110
Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA
Veprintsev, D. B., & Fersht, A. R. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm1040 · Cited by 109
Self-citationStructural evolution of C‐terminal domains in the p53 family
Ou, H. D., Löhr, F., Vogel, V., Mäntele, W., & Dötsch, V. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601764 · Cited by 108
Regulation of p53 tetramerization and nuclear export by ARC
Foo, R., Nam, Y., Ostreicher, M. J., Metzl, M. D., Whelan, R. S., Peng, C.-F., Ashton, A. W., Fu, W., Mani, K. M., Chin, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710017104 · Cited by 104
Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53
Jordan, J. J., Menendez, D., Inga, A., Nourredine, M., Bell, D., & Resnick, M. A. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000104 · Cited by 103
High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx
Czarna, A., Popowicz, G. M., Pęcak, A., Wolf, S., Dubin, G., & Holak, T. A. (2009) · Cell Cycle · doi:10.4161/cc.8.8.8185 · Cited by 99
Mechanism of folding and assembly of a small tetrameric protein domain from tumor suppressor p53.
Fersht, A. R., Mateu, M. G., & del Pino, M. M. S. (1999) · Nature Structural Biology · doi:10.1038/5880 · Cited by 98
Self-citation14-3-3 activation of DNA binding of p53 by enhancing its association into tetramers
Rajagopalan, S., Jaulent, A. M., Wells, M. A., Veprintsev, D. B., & Fersht, A. R. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn598 · Cited by 98
Self-citationStructure of the human p53 core domain in the absence of DNA
Wang, Y., Rosengarth, A., & Luecke, H. (2007) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444906048499 · Cited by 97
NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro
Krajewski, M., Ozdowy, P., D’Silva, L., Rothweiler, U., & Holak, T. A. (2005) · Nature Medicine · doi:10.1038/nm1105-1135 · Cited by 96
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
THIERS, B. H. (2008) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70921-3 · Cited by 94
p53-A natural cancer killer: Structural insights and therapeutic concepts
Römer, L., Klein, C., Dehner, A., Kessler, H., & Buchner, J. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600611 · Cited by 93
Mayer, S., Rüdiger, S., Ang, H. C., Joerger, A. C., & Fersht, A. R. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.06.044 · Cited by 92
Self-citationShangary, S., Ding, K., Qiu, S., Nikolovska-Coleska, Z., Bauer, J. A., Liu, M., Wang, G., Lu, Y., McEachern, D., Bernard, D., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0140 · Cited by 91
Crystal structure of a p53 core tetramer bound to DNA
Malecka, K. A., Ho, W. C., & Marmorstein, R. (2008) · Oncogene · doi:10.1038/onc.2008.400 · Cited by 87
Gordo, S., Martos, V., Santos, E., Menéndez, M., Bó, C., Giralt, E., & de Mendoza, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805658105 · Cited by 86
Members of the S100 family bind p53 in two distinct ways
Fernández-Fernández, M. R., Rutherford, T. J., & Fersht, A. R. (2008) · Protein Science · doi:10.1110/ps.035527.108 · Cited by 84
Self-citationComo, C. J. D., & Prives, C. (1998) · Oncogene · doi:10.1038/sj.onc.1202041 · Cited by 83
Kallen, J. A., Goepfert, A., Blechschmidt, A., Izaac, A., Geiser, M., Tavares, G., Ramage, P., Furet, P., Masuya, K., & Lisztwan, J. H. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809096200 · Cited by 75
Junk, D. J., Vrba, L., Watts, G. S., Oshiro, M. M., Martinez, J. D., & Futscher, B. W. (2008) · Neoplasia · doi:10.1593/neo.08120 · Cited by 74
Venot, C., Maratrat, M., Sierra, V., Conseiller, E., & Debüssche, L. (1999) · Oncogene · doi:10.1038/sj.onc.1202539 · Cited by 73
Mittl, P. R. E., Chêne, P., & Grütter, M. G. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444997006550 · Cited by 71
PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.
(2008) · PubMed Central · doi:10.3233/clo-2008-0440 · Cited by 68
Conformational stability and activity of p73 require a second helix in the tetramerization domain
Coutandin, D., Löhr, F., Niesen, F., Ikeya, T., Weber, T. A., Schäfer, B., Zielonka, E. M., Bullock, A. N., Yang, A. E., Güntert, P., et al. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.139 · Cited by 67
Cognate DNA Stabilizes the Tumor Suppressor p53 and Prevents Misfolding and Aggregation
Ishimaru, D., Bom, A. P. D. A., Lima, L. M. T. R., Quesado, P. A., Oyama, M. F. C., Gallo, C. V. D. M., Cordeiro, Y., & Silva, J. L. (2009) · Biochemistry · doi:10.1021/bi9003028 · Cited by 64
Jenkins, L. M. M., Yamaguchi, H., Hayashi, R., Cherry, S., Tropea, J. E., Miller, M., Wlodawer, A., Appella, E., & Mazur, S. J. (2009) · Biochemistry · doi:10.1021/bi801716h · Cited by 64
One billion years of p53/p63/p73 evolution
Белый, В. А., & Levine, A. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910634106 · Cited by 62
Inga, A., Monti, P., Fronza, G., Darden, T., & Resnick, M. A. (2001) · Oncogene · doi:10.1038/sj.onc.1204116 · Cited by 59
Dong, P., Tada, M., Hamada, J., Nakamura, A., Moriuchi, T., & Sakuragi, N. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9084-8 · Cited by 56
Ultraslow oligomerization equilibria of p53 and its implications
Natan, E., Hirschberg, D., Morgner, N., Robinson, C. V., & Fersht, A. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907840106 · Cited by 56
Self-citationInga, A., & Resnick, M. A. (2001) · Oncogene · doi:10.1038/sj.onc.1204457 · Cited by 54
Suad, O., Rozenberg, H., Brosh, R., Diskin-Posner, Y., Kessler, N., Shimon, L. J. W., Frolow, F., Liran, A., Rotter, V., & Shakked, Z. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.10.063 · Cited by 53
Structural Differences in the DNA Binding Domains of Human p53 and Its C. elegans Ortholog Cep-1
Huyen, Y., Jeffrey, P. D., Derry, W. B., Rothman, J. H., Pavletich, N. P., Stavridi, E. S., & Halazonetis, T. D. (2004) · Structure · doi:10.1016/j.str.2004.05.007 · Cited by 53
Mutational Analysis of the p53 Core Domain L1 Loop
Zupnick, A., & Prives, C. L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603387200 · Cited by 52
Restoration of p53 function leads to tumour regression in vivo
THIERS, B. H. (2008) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70920-1 · Cited by 50
Toledo, F., Lee, C. J., Krummel, K. A., Rodewald, L.-W., Liu, C.-W., & Wahl, G. M. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00999-06 · Cited by 46
The oligomerization domain of p53: Crystal structure of the trigonal form
Miller, M., Lubkowski, J. T., Rao, J., Danishefsky, A. T., Omichinski, J. G., Sakaguchi, K., Sakamoto, H., Appella, E., Gronenborn, A. M., & Clore, G. M. (1996) · FEBS Letters · doi:10.1016/s0014-5793(96)01231-8 · Cited by 42
Kinetic Partitioning During Folding of the p53 DNA Binding Domain
Butler, J. S., & Loh, S. N. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.05.060 · Cited by 41
Rosal, R. V., Pincus, M. R., Brandt‐Rauf, P. W., Fine, R. L., Michl, J., & Wang, H. (2004) · Biochemistry · doi:10.1021/bi035718g · Cited by 39
Adaptive Evolution of p53 Thermodynamic Stability
Khoo, K. H., Andreeva, A., & Fersht, A. R. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.08.013 · Cited by 32
Self-citationTRIMming p53 for ubiquitination
Tai, E., & Benchimol, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905997106 · Cited by 28
Galea, C. A., Bowman, P., & Kriwacki, R. W. (2005) · Protein Science · doi:10.1110/ps.051622005 · Cited by 27
Stabilising the DNA-binding domain of p53 by rational design of its hydrophobic core
Khoo, K., Joerger, A. C., Freund, S. M. V., & Fersht, A. R. (2009) · Protein Engineering Design and Selection · doi:10.1093/protein/gzp018 · Cited by 26
Self-citationBrown, C. J., Srinivasan, D., Jun, L. H., Coomber, D., Verma, C. S., & Lane, D. P. (2008) · Cell Cycle · doi:10.4161/cc.7.5.5488 · Cited by 25
A Fluid Salt-bridging Cluster and the Stabilization of p53
Lwin, T. Z., Durant, J. J., & Bashford, D. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.07.080 · Cited by 23
Mora, P., Carbajo, R. J., Pineda‐Lucena, A., del Pino, M. M. S., & Pérez‐Payá, E. (2007) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.21854 · Cited by 22
Cooperativity Dominates the Genomic Organization of p53-Response Elements: A Mechanistic View
Pan, Y., & Nussinov, R. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000448 · Cited by 22
Fen, C. X., Coomber, D., Lane, D. P., & Ghadessy, F. J. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.099 · Cited by 19
CARPs are E3 ligases that target apical caspases and p53
Yang, W., & El‐Deiry, W. S. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.11.4939 · Cited by 17
p53 — A Natural Cancer Killer: Structural Insights and Therapeutic Concepts
Römer, L., Klein, C., Dehner, A., Kessler, H., & Büchner, J. (2006) · ChemInform · doi:10.1002/chin.200702268 · Cited by 11
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer
Hodgkinson, C. L., Morrow, C. J., Li, Y., Metcalf, R. L., Rothwell, D. G., Trapani, F., Polanski, R., Burt, D. J., Simpson, K. L., Morris, K., et al. (2014) · Nature Medicine · doi:10.1038/nm.3600 · Cited by 694
Why are there hotspot mutations in the TP53 gene in human cancers?
Baugh, E. H., Ke, H., Levine, A. J., Bonneau, R. A., & Chan, C. S. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.180 · Cited by 607
The Genomic Landscape of Pediatric Ewing Sarcoma
Crompton, B. D., Stewart, C., Taylor-Weiner, A., Alexe, G., Kurek, K. C., Calicchio, M. L., Kiezun, A., Carter, S. L., Shukla, S. A., Mehta, S. S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-1037 · Cited by 566
Paleček, E., Tkáč, J., Bartošík, M., Bertók, T., Ostatná, V., & Paleček, J. (2015) · Chemical Reviews · doi:10.1021/cr500279h · Cited by 319
Metadata
- Authors
- Joerger, A. C., & Fersht, A. R.
- Venue
- Cold Spring Harbor Perspectives in Biology
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2010-02-10
- Volume
- 2
- Issue
- 6
- Pages
- a000919-a000919
- ISSN
- 1943-0264 (ISSN-L)
- OpenAlex
- W2097616194
- Cited by
- 357
- References
- 157
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.